BiotechTube

SYNB1353

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Homocystinuria

Conditions

Homocystinuria

Trial Timeline

Jul 7, 2022 → Nov 27, 2022

NCT ID
NCT05462132

About SYNB1353

SYNB1353 is a phase 1 stage product being developed by Synlogic for Homocystinuria. The current trial status is completed. This product is registered under clinical trial identifier NCT05462132. Target conditions include Homocystinuria.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05462132Phase 1Completed

Competing Products

3 competing products in Homocystinuria

See all competitors
ProductCompanyStageHype Score
PegtibatinaseTravere TherapeuticsPhase 3
72
Pegtibatinase + PlaceboTravere TherapeuticsPhase 1/2
36
PegtibatinaseTravere TherapeuticsPhase 3
72

Other Products from Synlogic

SYNB1934v1 + PlaceboPhase 3
69
SYNB1618 + SYNB1934Phase 2
44
SYNB1618 + PlaceboPhase 1/2
33
SYNB1020Phase 1/2
33
SYNB1891 + AtezolizumabPhase 1
25